Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV)
and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be
used in pivotal trial by assessing the steady-state pharmacokinetics and short-term efficacy
and safety